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1. Introduction
The necessity to cryopreserve certain tissues and cell types for their use in assisted reproduc‐
tion has allowed technique developments that improve the quality of treatments and help both
professionals and patients to perform these techniques. In this chapter we will talk about the
importance that cryopreservation has meant to assisted reproduction techniques and about
the benefit for patients of the advance and improvement of different cryopreservation
techniques, for example in the recent and increasingly demanded technique Egg Vitrification,
to preserve female fertility.
From the cryopreservation point of view sperm, oocytes, embryos and ovarian tissue will be
analyzed, by reviewing how different cryopreservation techniques have evolved up to
reaching the techniques used nowadays giving, furthermore, a vision of how they will be in
the future to optimize even further, the procedure increasing survival rates and viability of
gametes, embryos and ovarian tissue to 100%.
The Development of cryopreservation techniques, the increase in demand for cryopreserved
cells or tissues and the use of these techniques in cells or tissues from patients with infectious
diseases, has forced us to reduce the risk of contamination during the freezing process and the
risk of cross-contamination during the storage of this material. Recent publications that
demonstrate the survival of pathogens at low temperatures and possible contamination of the
cells or tissues stored have changed the laws of each country and the customs and protocols
used so far in the cryopreservation.
To understand the problem of contamination in cryopreservation we need to have an overview
of the current problem in which all researchers are concerned about, seeking a cryopreserva‐
tion protocol with good results but without contamination problems. Discussing the cryopre‐
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servation’s different techniques such as slow freezing, vitrification, kinetic vitrification (extra-,
hyper-, super-, ultra-fast vitrification) and the various components that help us understand
the difficult balance between technique, device used and the risk of contamination.
The device used, the protocol used and the cooling solution used can change the outcome of
cryopreservation and therefore we have to find a protocol for cryopreservation with a cooling
solution and a secure device to provide us good results free of contamination.
2. Slow freezing and Vitrification
Two are the most utilized methods for gamete cryopreservation: slow freezing and
vitrification. Slow freezing uses low concentrations of cryoprotectants which are associated
with chemical toxicity and osmotic shock. Vitrification is a rapid method that decreases cold
shock, without the risks of solution effects or crystallization, and uses high cooling rates in
combination with a high concentration of cryoprotectant [1].
Slow freezing is a conventional cryopreservation process in which a relatively low concentra‐
titon of cryoprotectant is used (1.5 M), it shows little toxicity to cells or tissue and requires
expensive equipment. As the cryoprotectant is added to cells, it results in initial cellular
dehydration followed by a return to isotonic volume with the permeation of cryoprotctant and
water. Generally, cells are cooled slowly using a controlled rate freezing machine, which allows
samples to be cooled at various rates; ovarian tissue is generally cryopreserved at 2° C/min
prior to ice seeding and 0.3° C/min after crystallization to ensure the tissue is dehydrated before
intracellular ice formation occurs. Optimal rates to minimize intracellular rates formation vary
among cells and tissue types [2].
It is generally believed that cell injury at low cooling rates is principally due to the concentra‐
tion of both intracellular and extracellular electrolytes and that cryoprotectants act by reducing
this build-up. Experimental data support this explanation, in fact the extent of damage to
human red blood cells during freezing in solutions of sodium chloride/glycerol/water can be
quantitatively accounted for by the increase in solute concentration. Furthermore, a given
degree of damage occurs at lower concentrations of solute in the presence of higher concen‐
trations of glycerol; it appears that glycerol contributes as element of damage itself [3].
Although initially reported in 1985 as a successful cryopreservation approach for mouse
embryos, vitrification has taken a backseat in human assisted reproduction. However, the
practical advantages of this cryopreservation method have more recently caught the attention
of many ART laboratories as a feasible alternative to traditional slow freezing methods. Since
1985 more than 2,100 publications can be found referring to the topic of “vitrification”, which
is further evidence of the burgeoning growth of interest in this cryopreservation technology.
One “drawback” considered by embryologists who are not familiar with the vitrification
technique, is the use of higher concentration of cryoprotectants, which does potentially mean
that the vitrification solutions are more toxic than their counterpart solutions used for
conventional slow freezing. However, with better understanding of the physical and biological
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principles of vitrification this has lead to numerous successful clinical applications of this
technique within the field of assisted reproduction. As of today, all developmental stages of
human embryos cultured in vitro have been successfully vitrified and warmed, with resulting
offspring. Today, slow freezing technology still has the longest clinical track record, and
greater ‘comfort level’ amongst embryologists. Nevertheless, vitrification with its increasing
clinical application is showing a trend of greater consistency and better outcomes when
compared to slow freezing technology. Therefore, when (not if) IVF programs overcome the
fear of the ‘unknown’, and take on the challenge of the short learning curve with vitrification,
then at that point vitrification will become the clinical standard for human embryo cryopre‐
servation.
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Cryopreservation  at  low  temperature  slows  or  totally  prevents  unwanted  physical  and
chemical change. The major disadvantage to using low temperature cryostorage is that it
can  lead to  the  rystallization  of  water,  and thereby this  approach can  create  new and
unwanted  physical  and  chemical  events  that  may  injure  the  cells  that  are  being  pre‐
served. Although the results achieved by slow freezing in many cases see  quite success‐
ful  [5,  6],  ice crystal  formation still  renders traditional slow-freezing programs generally
less  consistent  in  their  clinical  outcomes.  Another  downside  to  the  slow  freezing  ap‐
proach is the time to complete such freezing procedures for human embryos, which can
range from 1.5 to 5hrs.  This is  due to the fact  that  the slow rate of  cooling attempts to
maintain a v ry delicate balance between multiple factors that may result in c llular damage
by ice stallization and osmotic toxicity. Trad tionally slow-freeze embryo cryopreserva‐
tion has been a positive contributor to cumulative patient pregnancy rates, but ultimately
the limitations of current slow-rate freezing methods in ART have become more evident in
the shootout with vitrification-based cryostorage.
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Vitrification is one of the more exciting developments in ART in recent years that attempts to
avoid ice formation altogether during the cooling process by establishing a glassy or vitreous
state rather than an ice crystalline state, wherein molecular translational motions are arrested
without structural reorganisation of the liquid in which the reproductive cells are suspended.
To achieve this glass-like solidification of living cells for cryostorage, high cooling rates in
combination with high concentrations of cryoprotectants are used. A primary strategy for
vitrifying cells and tissue is to increase the speed of thermal conductivity, while decreasing
the concentration of the vitrificants to reduce their potential toxicity. There are two main ways
to achieve the vitrification of water inside cells efficiently: a) to increase the cooling rate by
using special carriers that allow very small volume sizes containing the cells to be very rapidly
cooled; and b) to find materials with rapid heat transfer. However, one has to take into account
that every cell seems to require its own optimal cooling rate, e.g., mature unfertilized oocytes
are much more sensitive to chilling injury than any of the cell stages of the pre-implantation
embryo. The earliest attempts using vitrification as an ice-free cryopreservation method for
embryos were first reported in 1985 [7]. In 1993 successful vitrification of mouse embryos was
demonstrated [8]. Furthermore, bovine oocytes and cleavage-stages were vitrified and
warmed successfully a few years later [9]. In 1999 and 2000 successful pregnancies and
deliveries after vitrification and warming of human oocytes were reported [10, 11]. Since that
time, and because it seems to be that both entities appear to be especially chill-sensitive cells
in ART, oocytes and blastocysts seem to receive a potentially significant boost in survival rates
by avoiding ice crystallization using vitrification [12]. In general, vitrification solutions are
aqueous cryoprotectant solutions that do not freeze when cooled at high cooling rates to very
low temperature. Interest in vitrification has clearly risen as evinced by the almost exponential
growth of scientific publications about vitrification. Vitrification is very simple, requires no
expensive programmable freezing equipment, and relies especially on the placement of the
embryo in a very small volume of vitrification medium (refered also as “minimal volume
approach”) that must be cooled at extreme rates not obtainable in traditional enclosed cryo-
storage devices such as straws and vials. The importance of the use of a small volume, also
referred to “minimal volume approach” was described and published in 2005 [13, 14]. In
general, the rate of cooling/warming and the concentration of the cryoprotectant required to
achieve vitrification are in inversely related. In addition, recent publications have shown the
dominance of warming rate over cooling rates in the survival of oocytes subjected to a
vitrification procedure [15, 16].
During vitrification, by using a cooling rate in the range of 2,500 to 30,000°C/min or greater,
water is transformed directly from the liquid phase to a glassy vitrified state. The physical
definition of vitrification is the solidification of a solution at low temperature, not by icecrys‐
tallization but by extreme elevation in viscosity during cooling [17, 18]. Vitrification of the
aqueous solution inside cells can be achieved by increasing the speed of temperature change,
and by increasing the concentration of the cryoprotectant used. However, a major potential
drawback of vitrification is the use of high concentration of cryoprotectant, and an uninten‐
tional negative impact of these cryoprotectants in turn can be their toxicity, which may affect
the embryo and subsequent development in utero. It is therefore essential to achieve a fine
balance between the speed of cooling and the concentration of the vitrifying cryoprotectants.
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This is necessitated by the practical limit for the rate of cooling, and the biological limit of
tolerance of the cells for the concentration of toxic cryoprotectants being used to achieve the
cryopreserved state. It is important to note that recently published papers [19, 20, 21, 22] have
shown that the use of relatively high concentration of cryoprotectants such as 15% (vol/vol)
ethylene glycol (EG) used in an equimolar mixture with dimethyl sulphoxide (DMSO) had no
negative effect on the perinatal outcomes from blastocyst transfers following vitrification when
compared with those from fresh blastocyst transfers.
Vitrification in principle is a simple technology, that is potentially faster to apply, and relatively
inexpensive; furthermore, it is becoming clinically established, and is seemingly more reliable
and consistent than conventional cryopreservation when carried out appropriately [23, 24].
Cryoprotectant agents are essential for the cryopreservation of cells. Basically two groups of
cryoprotectants exist: 1) permeating (glycerol, ethylene glycol, dimethyl sulphoxide); and 2)
nonpermeating (saccharides, protein, polymers) agents. The essential component of a vitrifi‐
cation solution is the permeating agent. These compounds are hydrophilic non-electrolytes
with a strong dehydrating effect. Furthermore, these CPAs are able to depress the “freezing
point” of the solution. Regarding the high concentration of cryoprotectant used for vitrifica‐
tion, and in view of the known biological and physiochemical effects of cryoprotectants, it is
suggested that the toxicity of these agents is a key limiting factor in cryobiology. Not only does
this toxicity prevent the use of fully protective levels of these additives, but it may also be
manifested in the form of cryo-injury above and beyond that seen occurring due to classical
causes of cell damage (osmotic toxicity and ice formation) during cryopreservation. In spite of
this, the permeating CPA should be chosen firstly by their permeating property, and secondly
on the basis of their potential toxicity. Because the permeating CPA is responsible for the
toxicity (the key limiting factor in cryobiology), different cryoprotectants have been tested for
their relative toxicity, and the results indicate that ethylene glycol (EG; MW 62.02) is the least
toxic followed by glycerol. Additionally, these highly permeating cryoprotectants are also
more likely to diffuse out of the cells rapidly and the cells regained their original volume more
quickly upon warming, thus preventing osmotic injury. Therefore, the most common and
accepted cryoprotectant for vitrification procedures is ethylene glycol (EG). Today EG is more
commonly used in an equimolar mixture with DMSO. Often additives are added to the
vitrification solution such as disaccharides. Disaccharides, for example sucrose, do not
penetrate the cell membrane, but they help to draw out more water from cells by osmosis, and
therefore lessen the exposure time of the cells to the toxic effects of the cryoprotectants. The
non-permeating sucrose also acts as an osmotic buffer to reduce the osmotic shock that might
otherwise result from the dilution of the cryoprotectant after cryostorage. In addition,
permeating agents are able to compound with intracellular water and therefore water is very
slowly removed from the cell. Hence the critical intracellular salt concentration is reached at
a lower temperature. Removal of the cryoprotectant agent during warming can present a very
real problem in terms of trying to reduce toxicity to the cells. Firstly, because of the toxicity of
the vitrification solutions, quick dilution of them after warming is necessary; and secondly,
during dilution water permeates more rapidly in to the cell than the cryoprotective additive
diffuses out. As a consequence of the excess water inflow the cells are threatened by injury
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from osmotic swelling. In this situation the non-permeating sucrose acts as an osmotic buffer
to reduce the osmotic shock. During warming using a high extracellular concentration of
sucrose (e.g., 1.0M) counterbalances the high concentration of the cryoprotectant agents in the
cell, as it reduces the difference in osmolarity between the intra-and extracellular compart‐
ments. The high sucrose concentration cannot totally prevent the cell from swelling, but it can
reduce the speed and magnitude of swelling [25, 26, 27].
3. Sperm
Human spermatozoa can be successfully cryopreserved and utilized. Cryopreservation now
plays an essential role in fertility preservation under the following scenarios:
• couples undergoing infertility treatment.
• cancer patients undergoing gonadotoxic chemotherapy or radiation.
• patients undergoing certain types of pelvic or testicular surgeries
• patients suffering from degenerative illnesses such as diabetes or multiple sclerosis; spinal
cord disease or injury.
• men undergoing surgical sterilization such as vasectomy
• screening and quarantine of donor semen samples
Many advances in reproductive medicine in the past five decades have made cryopreservation
of human spermatozoa an invaluable tool for the clinical management of infertility and sperm
banking. The advent of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI)
with microsurgical sperm handling techniques along with advances in female gamete
acquisition have resulted in an increased demand for the cryopreservation of semen and tissue
samples, often containing a very limited number of spermatozoa. Sperm cryopreservation also
makes it possible for cancer patients to preserve their fertility prior to gonadotoxic chemo‐
therapy or radiation. Applications of sperm banking are not limited to cancer patients but
extend to patients undergoing certain types of pelvic or testicular surgeries; those who suffer
from degenerative illnesses such as diabetes or multiple sclerosis; spinal cord disease or injury;
and persons in occupations where a significant risk of gonadotoxicity prevails. Sperm
cryopreservation is also available to men undergoing surgical sterilization such as vasectomy,
in the event that children may be desired in the future. Another use for semen cryopreservation
is to allow donor semen samples to be quarantined while appropriate screening is performed
to prevent the transmission of infectious pathogens during therapeutic donor insemination
(TDI) [28].
In cases of severe male infertility, single or lesbian women, the use of donor sperm is the only
approach to address fertility issues [29, 30]. Advances in sperm cryopreservation have created
opportunities for many families to achieve pregnancies through therapeutic donor insemina‐
tion or IVF with donor sperm.
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At present, some 30,000 births per year worldwide are attributable to frozen donor sperm
inseminations [31].
Although major improvements have been made in sperm cryopreservation, there are many
unresolved technical issues. Since freezing protocols differ between types of cells, the ideal
conditions for human sperm freezing and thawing need to be perfected. To add more com‐
plexity, samples with abnormal semen parameters, such as severe oligospermia or high
seminal fluid viscosity, often require unique cryopreservation conditions. For example, the
particular cryoprotectants can affect cooling rates. In addition, storage temperature can
significantly influence cryopreservation outcome. Liquid nitrogen (LN2) can offer long-term
survival of spermatozoa due to essentially absent metabolic activity, such as chemical reac‐
tions, genetic modification or aging of cells [32]. A conventional slow freezing protocol has
been in use for many years and very little has changed in terms of methodology and reagents.
While freezing aims to preserve cells it can also easily destroy them if certain precautionary
steps are not taken into consideration. During cryopreservation cells and tissue undergo
dramatic transformation in chemical and physical characteristics as the temperature drops
from+37 to-196°C. The cells can lose up to 95% of their intracellular water. The concentration
of solutes increases considerably, triggering the possibility of osmotic shock. Moreover,
potential intracellular ice crystallization and mechanical deformation by extracellular ice may
cause significant injury leading to cell death. Furthermore, if cells survive freezing, they might
sustain additional damage during the thawing process due to osmotic shock, uncontrollable
swelling and ice re-crystallization [33].
Remarkably, the first reference of empirical sperm freezing dates as far back as the late 16th
century, but it was only with the discovery in 1937 by Bernstein and Petropavlovski that
glycerol can aid spermatozoa in surviving long term freezing, that sperm cryopreservation
became practical. Expansion of artificial insemination for the dairy industry led to further
important research in the field of cryobiology [34]. Shortly after these practices were initiated
with animals, the first pregnancies were reported in humans after insemination with frozen
spermatozoa.
The next milestone was the discovery of the possibility to store human spermatozoa in
LN2at-196°C, resulting in superior recovery rates compared to storage at higher temperatures
between-20 and-75°C. After the era of empirical freezing; cryobiology matured to its funda‐
mental stage, focusing on the biophysical and biochemical principals of cryopreservation,
further advancing the field [35]. A comprehensive review of the historical background of sperm
freezing was recently published and is recommended for readers looking for more details [36].
3.1. Cryopreservation of epididymal and testicular spermatozoa
Couples with male factor infertility represent 30 to 40% of the infertile population. Azoosper‐
mia accounts for 10% of cases of confirmed male infertility, and often requires surgical retrieval
of spermatozoa. Since the introduction of ICSI, many cases of severe male infertility can now
be successfully treated. Cryopreservation of surgically retrieved spermatozoa is a valuable
component in the effective management of male infertility, reducing the necessity of repeat
surgeries. Diagnostic sperm retrieval prior to IVF has several benefits including the possibility
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of freezing spermatozoa for future use, or if none are retrieved, initiation of the IVF stimulation
cycle can be postponed or avoided. Testicular spermatozoa have been utilized to achieve
pregnancy in couples with severe male factor infertility, with reported pregnancy rates similar
to ejaculated spermatozoa, according to a meta-analysis study [37]. In the case of obstructive
azoospermia, recovery of spermatozoa by aspirations varies from 45 to 97% [38, 39]. In cases
of non obstructive azoospermia recovery depends on the degree of testicular pathology and
varies from 0 to 64% [40, 41]. A second or third surgery can increase the chance of complications
including hematomas, inflammation, testicular devascularization, fibrosis and permanent
testicular damage [42]. To avoid this, if pregnancy is not achieved during the first ICSI attempt,
a repeat of the surgical procedure would not be required if a portion of the surgical specimen
has been banked. Cryopreservation of surgically retrieved spermatozoa can also aid the
coordination of oocyte retrieval and avoids the pressure of having the urologist available on
the day of the ICSI procedure. Usually the number of spermatozoa obtained during a surgical
procedure is limited, and in the case of testicular sperm they may not be fully matured. In the
future, if no mature spermatozoa are recovered, spermatogonial stem cells or early germs cells
could potentially be matured in vitro and used for fertility treatments [43].
There are significant technical challenges for successful cryopreservation of testicular tissue
due to its complex structure and intracellular interactions. Different cells of testicular tissue
will have dissimilar responses to cryopreservation and require different concentration of
CPAs. Freezing larger pieces of tissue is not advisable as it would increase resistance of heat
transfer and penetration of CPAs leading to variation in cooling rates within different parts of
the tissue. In addition, seminiferous tubules capture liquid and increase chances of ice
formation [33]. To avoid these difficulties, cryopreservation of smaller tissue fragments or
mincing tissue prior to freezing has been advocated [44].
3.2. Cryopreservation in oncological patients
Quite often in clinical practice, the long term effects of cancer therapy on a patients’ ability to
have children in the future is not adequately addressed [45]. While the priority is to eliminate
the cancer and save their life, fertility preservation especially among adolescent or young
adults to ensure the potential of procreation with their own gametes after treatment, needs to
be considered. Impaired spermatogenesis has been demonstrated before treatment in some
patients with malignancies, depending on their location (eg. testicular cancer) or type
(eg.Hodgkin’s lymphoma) [46]. Current treatment options such as surgery, chemotherapy
and/or radiation can impair spermatogenesis and sexual function and lead to temporary or
permanent infertility [47].
The scale of negative effects of cancer treatment on spermatogenesis depend on the specific
gonadotoxicity of administered chemotherapeutic agents, number of chemotherapy treatment
cycles, radiotherapy field location and dosage, type and stage of the cancer, and age of the
patient. Considering combination cancer therapy, uncertainty in individual esponse to
treatment and the large number of confounding variables, it becomes very challenging to
assess the risk of iatrogenic infertility in many patients. The ability of cancer survivors to have
their own biological offspring is very important for many oncology patients, especially at
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younger ages [48]. Advances in early diagnostic investigation and treatments have led to
increasing numbers of young cancer survivors.
Cryopreservation of semen has changed the reproductive prospects for young patients
diagnosed with cancer. Unfortunately, banking services continue to be underutilized since
cancer patients and their families are not always informed about the potential fertility risks
associated with cancer treatments, or the availability of banking. According to some surveys,
less than 20% of patients undergoing chemotherapy or radiation treatment are informed about
the adverse effects of such treatment on spermatogenesis or are offered sperm banking for
fertility preservation. Cancer patients are usually under huge physiological and time pressure
to make cryopreservation decisions while dealing with a life threatening situation. To com‐
plicate matters, some young patients are unable to produce semen samples by masturbation.
In such cases, PVS or electro-ejaculation under general anaesthetic might be required. Surgical
retrieval of testicular tissue may be an option for prepubertal boys who are not capable of
producing mature sperm. Testicular tissue cryopreservation has been reported in boys with
cryptorchidism to preserve fertility [49]. Cryopreserved testicular tissues can be autografted
to restore reproductive functions; however recurrence of neoplastic process is a concern in
oncology patients and such procedures are still considered to be experimental [43]. A multi-
disciplinary team approach is important to ensure that patients have the opportunity to
preserve their fertility potential if they elect to do so.
The posthumous use of semen is an entirely separate and complex ethico-legal subject. The
ethical and legal aspects of posthumous assisted reproduction have been recently addressed
by the European Society of Human Reproduction and Embryology Task Force on Ethics and
Law [50].
4. Oocytes
The cryopreservation of human oocytes constitutes an important step forward in Assisted
Reproductive Technology (ART) despite the fact that for more than 2 decades oocyte cryopre‐
servation has long been the focus of unsuccessful efforts to perfect its clinical application. More
recently, vitrification as an alternative to traditional slow freezing protocols has been shown
to provide high degrees of success in vitrified metaphase-II human oocytes. Although oocyte
cryopreservation historically has low efficiency mainly because of low rates of survival,
fertilization, and cleavage, data on ~ 2000 “frozen oocyte” babies born worldwide since 1986
exists. The question arises as to what makes oocytes so unique compared to embryos, besides
differences in cell size and membrane permeability? Oocytes have a low volume-to surface
ratio; hence they are less efficient at taking up cryoprotectant and at loosing water. Other
differences to be considered are a) that the maternal DNA is held suspended in the cytoplasm
on the meiotic spindle & not within the protective confines of the nuclear membrane, therefore
damage in the DNA and microtubules could explain the limited success of oocytes, b) the
oocyte is arrested in a state primed for activation, and c) the changes in its environment can
cause parthenogenetic activation. What are the applications then for oocyte cryopreservation
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in the US? One application would be to preserve fertility in women with malignant/prema‐
lignant conditions who would have to undergo treatment that might negatively impact their
future ability to have children (50,000 per year <40 yr old), also in women who may want to
delay childbearing (‘clock-tickers’) because of their careers, partnership status or psychologi‐
cal/ emotional reasons. A very interesting approach is donor oocyte banking, which makes the
donor-recipient cycle more convenient by facilitating the “egg donation” and allows quaran‐
tining of the oocytes, which provides a unique advantage in economy as well as feasibility.
Other applications are if a male is unable to produce a semen sample on the day of egg retrieval
and or it could also eliminate ethical/moral questions of producing extra embryos. Overall,
oocyte cryostorage offers an opportunity to reduce number of embryos generated per IVF
cycle, and therefore lessening the pressure on the patient to increase the number of fresh
embryos transferred. In addition, while also reducing embryo cryostorage it has the benefit of
helping women “retain ownership” of their ability to be genetic parents at a time of their
choosing, a time of greater convenience & health. The live born babies from cryopreserved
oocytes have shown no apparent increase in congenital anomalies. Although 13 years later
after the first slow-freeze birth, the number of reported babies born as a result of vitrified
oocytes is now approaching that of slow-frozen oocytes without any increasing risk in
congenital abnormalities [51]. Vitrification of oocytes does not appear to increase risks of
abnormal imprinting or disturbances in spindle formation or chromosome segregation [52]. It
has the greatest potential for successful oocyte cryopreservation and with its increased clinical
application is showing a trend to greater consistency and better outcomes (similar to outcomes
between fresh or warmed oocytes). Vitrification of oocytes, when applied to properly screened
patients, will be a useful technology in reproductive medicine practice and will constitute a
major step forward in ART.
Fortunately to date, no significant increase in abnormalities has been reported from these
cryostored oocyte pregnancies [53], regardless of the historical concerns that cryopreservation
of mature oocytes might disrupt the meiotic spindle and thus increase the potential for
aneuploidy in the embryos arising from such eggs. These concerns have mostly been allayed
by publications that show no abnormal or stray chromosomes from previously frozen oocytes
[54], and FISH comparison of embryos from fresh and thawed oocytes show no increase in
anomalies [55]. There also appears to be adequate recovery of the meiotic spindle post-
cryopreservation whether using conventional or vitrification technology [56, 57, 58]. The
scientific literature on oocyte cryopreservation grows daily it seems. Most reports focus on
clinical pregnancy rates [59, 60], and as such while this data is helpful to increase our confidence
in the technology, it does little to research new directions for oocyte cryopreservation.
5. Embryos
In 1983, Trounson and Mohr [61] announced the first pregnancy from a previously frozen
human embryo obtained from in vitro fertilization (IVF). The first live birth after embryo
cryopreservation  was  reported  in  1984  in  Australia,  and  the  first  in  the  United  States
followed in 1986. Since that time, cryostorage and subsequent use of human embryos has
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become standard practice in assisted reproductive technology (ART) and is now involved
in a significant proportion of all infertility treatments. In fact, the 2002 National Summary
of  Fertility  Centers  Report  (NSFCR)  determined  that  97%  of  the  391  American  centers
reporting to the Society for Assisted Reproductive Technology (SART) offer cryopreserva‐
tion [62]. Hoffman et al. [63] surveyed all SART-reporting clinics in the United States with
regard  to  their  cryopreservation  practices  and  also  found  that  virtually  all  of  the  340
responding clinics freeze embryos and store them on site, accounting for over 400,000 frozen
embryos as of 2002 [64].
Advances in assisted reproductive technologies have expanded procreative options for many
people experiencing infertility. With the evolution of in vitro fertilization (IVF), more embryos
often result from each cycle of ovarian stimulation than can safely be returned to a woman’s
uterus for implantation [65]. To reduce multiple gestations and their morbidity, avoid embryo
destruction, improve cost effectiveness, and preserve future options for infertile couples,
embryo cryopreservation (freezing) has developed as a routine practice in most IVF clinics [66].
Once embryos are frozen, they may be used for future pregnancy attempts, donated to another
couple, designated for stem cell or other research, or discarded.
Cryopreservation allows the transfer of a limited number of embryos back to the uterus and
the storage of the remaining embryos for future use, thus maximizing the cumulative effec‐
tiveness of an in vitro fertilization (IVF) cycle [67]. In addition, cryopreservation makes feasible
the postponement of embryo transfer (ET) in a future cycle, thus decreasing the incidence of
ovarian hyperstimulation syndrome in high-risk patients, while it maintains the probability
of pregnancy [68].
Cryopreservation of embryos also has an enormous potential in Preimplantacion Diagnosis
programmes (PGD). Therefore, not only does it allow us to conserve those normal embryos
not transferred, but can also benefit hyporesponsive patients thanks to the accumulation of
embryos in cycles [69]. An extension of embryo freezing is the embryo donation program, by
which, following the course of Article 11 b of the current legislation (Law 14/2006, May 26),
many couples that are not subsidiaries of Assisted Reproduction Techniques, may resort to
these thanks to the anonymous donation of surplus embryos from IVF [69]. The embryonic
stage in which we will perform cryopreservation is key in obtaining acceptable results, not
only in embryonic survival rates, but in implantation and birth rates too. Besides a correct
embryo selection of the best quality embryos is crucial for success in the cryopreserved embryo
transfer Programme [69]
Conventional cryopreservation of pronuclear zygotes (2PN) is well established in countries
such as Germany where freezing of later stage human embryos is by law or by ethical reasons
not allowed. The time to complete the conventional protocol to cryopreserved zygotes is 98min.
In Germany the clinical pregnancy outcomes arising from the frozen/thawed 2PN cycles is
about 18%, with an implantation of around 10% per embryo transferred. The time to complete
vitrification of zygotes requires approximately 12min. Recently successful vitrification of 2PN
with high survival (~ 90%), cleavage rates on day-2 (>80%), and blastocyst formation of 31%
and pregnancies were reported [70, 71, 72, 73]. Zygote vitrification implemented as a clinical
setting can provide a clinical pregnancy rate of close to 30%, with an implantation rate of 17%
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[73]. The pronuclear stage appears well-able to withstand the vitrification and warming
conditions, which is probably due to the significant membrane permeability changes that occur
post-fertilization; such changes to the oolemma may also make it more stable and able to cope
with the vagaries of the cold-shock and striking osmotic fluctuations that occur during the
vitrification process.
Activation of the embryonic genome occurs after the 8-cell stage (3 days post oocyte retrieval)
is reached [74]. If the activation does not occur, the embryo will not survive further. Therefore,
the improvement of human IVF outcomes requires identification of embryos that will progress
beyond the 8-cell stage. Blastocyst culture (5 days post oocyte retrieval) allows for the transfer
of embryos that clearly have an activated embryonic genome. This requires that the elimination
of embryos in extended culture from day 3 to day 5 should depend solely on their inherited
survival potential and not be a consequence of an adverse effect exerted by the sequential
media used for culture beyond day 3. Additional advantages in cryopreserving at the blasto‐
cyst stage are: 1) At this stage a lower numbers of embryos can be transferred in fresh cycles,
resulting in less high order multiple pregnancies, 2) The same is true for cryopreserved
blastocysts showing higher pregnancy rates and implantation per thawed embryo transferred,
3) Approximately 120 hours (day five) into development the healthy human embryo should
be at the blastocyst stage comprised of some 50 to 150 cells, of which about 20 to 30% make up
the inner cell mass (ICM), the remainder making up the trophectoderm (TE), 4) the higher cell
number allows better compensation for cryo-injuries, which results in greater viability and
faster recovery, 5) the cytoplasmatic volume of the cells is lower, thus the surface-volume ratio
is higher, and that in turn makes the penetration of the cryoprotectant faster, and 6) on average
fewer embryos per patient were frozen-stored, but each one when thawed has a greater
potential for implantation [75].
6. Cryopreservation of ovarian tissue
Cryopreservation of ovarian tissue is of interest to women who want fertility preservation
beyond the natural limit, or whose reproductive potential is threatened by cancer therapy, for
example in hematologic malignancies or breast cancer. It can be performed on prepubertal
girls at risk for premature ovarian failure, and this procedure is as feasible and safe as
comparable operative procedures in children.
At birth, the ovaries contain the lifetime complement of primary oocytes which are arrested
in the prophase stage of meiosis 1 and are surrounded by a single-layered epithelium to form
the primordial follicles. Ovarian cortex presents several advantages when compared with
isolated oocytes:
• It contains the important pool of growing follicles.
• It does not necessitate the in vitro maturation/in vitro fertilization /embryo culture steps if
it is associated with grafting.
• No previous ovarian stimulation is necessary.
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Consequently cryopreservation of ovarian cortex is an alternative to cryopreservation of
isolated oocytes or embryos. It could be used as an emergency preservation and as infertility
therapy method for valuable animals. Ovarian cortex cryopreservation has been developed in
human in order to preserve fertility in young women submitted to gonadotoxic therapy [76,
77]. In human newborns were obtained after orthotopic autograft of frozen-thawed ovarian
cortices [78].
It is obvious that, to achieve successful cryopreservation of ovarian tissue, it is essential to
maintain the functional status of the whole mixture of different cell types: oocytes, granulosa
cells, epithelial cells, fibroblasts… This represents a major difficulty, because the optimum
kinetic of cooling is different for each cell type. Oocytes are large cells, with a low surface to
volume ratio, surrounded by zona pellucida. Immediately adjacent to the oocyte are corona
radiata cells that have long cytoplasmic extensions which penetrate the zona pellucida, ending
in oocyte membrane. These processes and gap junctions are important in the metabolic
cooperation between the oocyte and surrounding layers of granulosa cells, which form the
cumulus-oocyte complex during the growth phase. Consequently, at the opposite to cryopre‐
servation of isolated cells, a cryopreservation protocol for a tissue represents a compromise
between the requirements of the different constitutive cells.
The early work on ovarian tissue cryopreservation was performed in animal studies: rabbit
[79] and rat [80, 81]. The earliest positive results were obtained when glycerol (15%) plus serum
were used as cryoprotective agents (CPAs) for cryopreservation of rabbit granulosa cells, via
a slow cooling protocol [79]. An equilibration period was necessary to achieve CPA penetration
into the tissue. For this reason small samples were recommended. A rapid rewarming by
plunging the samples into a water bath at 40°C was the most effective procedure [80]. Normal
offspring were obtained from mice with orthotopic ovarian grafts of tissue that had been frozen
and stored at-79°C [82]. Vitrification of ovarian tissue was also investigated. Nevertheless,
Isachenko et al suggested that in human, low freezing protocols were more promising than
vitrification protocols [83].
This technique has also been developed in rabbit [84], mouse [85], rat [86],  ewe [87, 88],
cow [89]. Vanessa Neto and her group [90] have obtained newborn rabbits after autograft‐
ing of cryopreserved ovarian cortex. Also, their team developed this technique in cat [90]
and dog [91].
Several techniques have been applied to ovarian cortex cryopreservation: slow freezing,
vitrification. Simultaneously to ovarian tissue cryopreservation, numerous researches have
been conducted about ovarian tissue grafting: orthotopic, heterotopic, auto-, allo-and hetero-
grafting [92].
The most common cryopreservation method is the slow freezing procedure, consisting of an
initial slow, controlled-rate cooling to subzero temperatures followed by rapid cooling as the
sample is plunged into liquid nitrogen for storage (−196°C). At such a low temperature,
biological activity is effectively stopped, and the cells functional status may be preserved for
centuries. However, several physical stresses damage the cells at these low temperatures.
Intracellular ice formation is one the largest contributors to cell death; therefore, freezing
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protocols use a combination of dehydration, freezing point depression, supercooling, and
intracellular vitrification in an attempt to avoid cell damage.
Currently used ovarian cortex cryopreservation protocols have been direct, or slight modifi‐
cations of the methods developed for isolated oocytes and embryos. There were primarily
developed by trial and error adjustments of cooling and warming rates, and choice of CPA
and CPA concentrations. However, because there are a large number of protocol variables
potentially affecting cell viability, an exhaustive experimental search for the optimal combi‐
nation of these parameters has long been considered to be prohibitively expensive in terms of
time and resources.
6.1. Chemical and physical parameters affecting equilibration and freezing processes of
ovarian tissue in mammalian species
The result of a cryopreservation process is influenced by several chemophysical parameters
affecting directly or not the functions and the integrity of the ovarian cells along the freezing
process, from the equilibration to the thawing. Among these parameters, the method of
equilibration, the freezing rate, the composition of the freezing solution and notably the nature
of the permeating CPAs and the non-permeating CPAs, the concentration of each CPA, the
use of serum, or the rate of thawing may be investigated to know the relative influence of each
of them and the induced cell injuries.
In general, we can expect coupled flows of water and CPAs when CPAs are added, during
freezing, thawing and when CPAs are removed from the cells, resulting in a series of anisos‐
motic conditions. During freezing, the cells dehydrate and shrink and remain shrunken during
storage, but return to their isosmotic volume upon thawing. Finally, the cells are subjected to
potentially lethal swelling upon CPA dilution and removal. During the controlled slow cooling
extracellular ice formation is induced (seeding) at a temperature just below the solutions’
freezing point, and then the cooling continues at a given rate in the presence of a growing
extracellular ice phase, which raises the extracellular solute concentration in the unfrozen
fraction and results in water being removed from the cell via exosmosis.
Permeating CPAs, such as glycerol, dimethyl sulfoxide, ethylene glycol or propylene glycol
are typically included in the cryoprotective medium, to protect the cells against injury from
the high concentrations of electrolytes that develop as water is removed from the solution as
ice. During the equilibration step the inner cell water is partly replaced by the permeating
CPAs. However, the CPAs can be damaging to the cells, especially when it is used at high
concentrations. The toxicity can be reduced by decreasing the time or the temperature of the
equilibration step [93]. But equilibration at low temperatures requires increasing the exposition
time to freezing solution. Furthermore, the CPAs may have dramatic osmotic effects upon the
cells during their addition and their removal.
Consequently, the use of several steps of increasing concentrations of CPAs during the
equilibration allows reducing the osmotic gradient. The cells exposed to such permeating
CPAs undergo initial dehydration, followed by rehydration, and potential gross swelling upon
removal. This osmotic shock may generate membrane damages by mechanical means and
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predisposition of the cell to injuries during the other steps of cryopreservation, or even cell
death [94]. These kinds of damages could be reduced by using cells surfactant such as serum.
During the freezing step, the follicular preservation depends on the nature and the concen‐
tration of the CPAs.
Control of the cooling and warming rates is also crucial, as the freezing/thawing rates and the
temperature of seeding also influence the ice properties. If cells are cooled too rapidly during
the controlled slow cooling process, water does not exit the cells fast enough to maintain
equilibrium and, therefore, the oocytes and other ovarian cells freeze intracellularly, resulting
in death in most cases. If cooling is too slow, the long duration can cause ‘solution effects’
injury resulting from the high concentration of extra-and intracellular solutes, probably due
to the effects of the solutes on the cellular membrane or through osmotic dehydration. During
warming the small intracellular ice crystals might subsequently undergo recrystallization,
forming bigger ice crystals that rupture the cell membrane, thus leading to fatal damage.
Finally, the thawing and the removal of the CPA depend on the temperature and on the
presence of non-permeating CPA limiting the osmotic swelling during rinsing.
7. Contamination in cryopreservation
One of the first thing we must learn is to differentiate their respective importance are the
concepts of contamination and cross contamination of samples. The first relates to the con‐
tamination of the sample by freezing or by direct contact with the cooling solution and the
second refers to the contamination of the sample within the common container which is in
contact with all cryopreserved samples, some samples may be contaminated or the liquid
nitrogen (LN2) might be contaminated producing a possible cross-contamination. The
potential for disease transmission and pathogen survival through contaminated LN2 has been
proposed by many authors [95-97], and the evidence of contamination in human patients has
been described for different pathogens [98-104]. It has to be stated that none of the reported
infections after insemination or ET in humans and domestic animals can be clearly attributed
to the applied cryopreservation and storage procedure but the use of safe cryopreservation
protocol is very important to avoid human cell contamination or cross contamination in
common LN2 tanks.
Although cryopreservation had a boom in the mid 70's and early 80's with the opening of the
first sperm banks in America and Europe, it was not until the mid-80's when we saw the need
for biological samples cryopreserved in quarantine and the lack of screening leads to infection
of several recipients that had been inseminated with semen samples from donors HIV+those
unaware of their disease [105]. In these cases it was found that samples stored in the same
containers with frozen HIV+samples were not contaminated, otherwise in 1995, six patients
undergoing cytotoxic treatments hermetic problems developed an outbreak of acute hepatitis
B after undergoing an autologous cryopreserved material that had been stored in the same
cryogenic container as other patients infected with hepatitis B [106].
The Maining of Cryopreservation for in-vitro Fertilization Patients
http://dx.doi.org/10.5772/58746
97
7.1. Cells and tissue contamination
In the field of assisted reproduction, although it hasn’t been detected any contamination in the
cryopreservation of gametes and embryos, the probability and the occurrence is low, the risk
is not zero so it is recommended to follow the rules in biosecurity manuals for both the physical
and chemical risk as well as the risk of contamination and cross contamination of samples.
The case in 1985 where there was infection with hepatitis B in the cryopreserved samples [106]
the infection was due to an error in packaging and storage of samples. With time a deterioration
of the bags containing infectious material causing the infection of the LN2 and other samples
was observed. Further studies have shown that the storage of samples is decisive. There is
evidence that frozen samples in hermetically sealed straws are not contaminated even if they
are in contaminated containers with contaminated LN2 and LN2 does not contaminate
infective biological samples that were frozen in a sealed container [107,108] During the
cryopreservation, biological samples go through many processes before being cryopreserved.
In the case of IVF cells are subjected to a phase of procurement, fertilization, development,
transfer and finally cryopreservation. This represents an approximate 6-day process in which
many factors can affect the contamination of the sample at the end of the process. We can find
contamination or cross-contamination in the following cases [109]:
• Handling contaminated biological samples (semen, follicular fluid, tissue, etc.). Without
precautions to avoid contamination outside the base plate to be used for conservation
(cryotube, straw, etc.). It is very important to disinfect and clean the container before filling
it with LN2 [110]. In this regard to ensure an adequate level of biosafety a study is needed
of infectious diseases transmissible from any patient or donor who wants to freeze any
samples. According to Castilla [111] the clinic policy for a donor with infectious diseases is
radically different to that of a patient with any of these diseases wanting to freeze biological
material for autologous use. In the first situation, the biological material at hand will not
freeze. In the second, the biological material should be frozen but with measures that we
discuss later. Screenings for infectious diseases that normally must be submitted are: To
analyse serological studies for syphilis, hepatitis and HIV. To analyse the clinical studies
infective clinical phases: toxoplasmosis, rubella, herpes virus, cytomegalovirus (CMV),
Neisseria gonorrhoeae and Chlamydia trachomatis. These tests are required for donors of
semen every 6 months. As the risk of disease transmission during storage in LN2 is mainly
viral. Interestingly, the American Society of Fertilisation [112], ESHRE [113], British
Andrology Society (BSA) [114] and the Spanish Association of Tissue Banks (AEBT) [115]
also recommend serologic screening for CMV, not just clinical. The presence of CMV in
semen has been associated with active disease (anti-CMV IgM+or recent seroconversion
anti-CMV IgG+). Similarly, these companies recommend performing serologic tests for
HTLV-I and HTLV-II. But although it is clearly demonstrated the transmission of human
papilloma virus by using LN2 cryotherapy and has been shown IUI transmission of herpes
simplex virus (HSV) [116], none of the scientific associations mentioned above recommend
a culture for detection or serological studies of HPV donors or patients with infection who
are going to freeze biological material because the analysis to detect these deceases are not
very sensitive. As rubella serologic screening of donors, its low prevalence in this population
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means that serological tests have a low positive predictive value, making it unadvisable.
Finally, we believe a patient who needs to freeze some reproductive biological material
should have at least one serology for HIV, hepatitis B and C. This proposal is consistent with
the recommendations of the AEBT for cryopreservation of semen [115].
• Use of contaminated culture media. In these cases the degree of cross-contamination would
reach very high levels having an impact on many patients. Although the preparation of
embryo culture media and sperm extenders from specific ingredients are avoided in human
clinics, it continues to be a common practice in animal ART [117]. Nevertheless, many
ingredients of embryo culture media and sperm extenders act as stabilizers for many micro-
organisms at freezing temperatures (milk, serum or serum albumin, sucrose, sorbitol and
other sugars). Unfortunately, the most common cryoprotectors (CPs) in applied oocyte
cryopreservation and embryo (glycerol, DMSO, ethylene glycol, propylene glycol, methanol
etc.) are toxic for cells. Also bacteria and viruses efficiently protect from cryoinjuries, eg
Concentrations of DMSO as low as 5% enveloped viruses defend against the trauma of
freezing [118]. The Fact That microorganisms survive in association with germplasm is not
only important from the potential of disease transmission by embryo transfer to recipients,
but also in approaches to the storage of samples for testing and health certification of
embryos or international movement. On the other hand we must also bear in mind that all
culture media containing antibiotics to prevent or limit survival of microorganisms.
• Conservation of contaminated material or straws cryotubes closed or sealed badly flawed
causing the breakdown of the frozen straw, leaving the contaminated sample directly
exposed to the LN2 tank risking contaminating the other samples. Closed systems can be
sealed in many ways (thermal sealer, ultrasound sealer, radiofrequency sealer, polyvinyl
alcohol powders, and solid caps). Given the sealing time and the temperature reached does
not affect the cryopreserved sample, we have to ensure that the seal is airtight and that the
device is built of resistant material to low temperatures of LN2 (Ionomeric resins, quartz
glass capillary, Polyvinyl chloride, Polyethylene glycol tetralato, etc).
• Using contaminated LN2 during the freezing process. In this case we have proposed some
solutions that we will see later.
• Poor source management of LN2 from our supplier contaminating commercial LN2 that
comes to our lab in the process of manufacture or transportation and filling ourcontainers.
• For transportation of contaminated material in containers. Storage containers should be
emptied and cleaned periodically due to the risk of lost straws or small particles of conta‐
minated material that falls to the bottom of a large container [119,120]. Most of the companies
of LN2 containers provide cleaning protocols. The main problem is the cleaning of transport
cylinders called "dry" because the material that absorbs the LN2 in these bottles is difficult
to sterilize. Bielanski [121] describes a method of disinfection of commercial dry shippers
with two different types of a LN absorbent. Based on the results presented, it appears that
solutions of sodium hypochlorite and ethylene oxide are equally useful for the disinfection
of dry shippers constructed with a hydrophobic LN absorbent. In contrast, for dry shippers
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without a hydrophobic LN absorbent it is advisable to use gas only for decontamination in
order sterilization to avoid their damage by liquid disinfectants.
• The air in the room. If the air that reaches the lab comes from another area that could be
contaminated and there isn’t a good filter. Some laboratories do not have filtration systems
or positive pressure to prevent air contamination.
• Operators. If they are infected then that can lead to contamination by contact or peeling
during processing of samples or the handling of cryogenic tanks. Staff must meet certain
health and hygiene conditions: negative serology for HIV, HCV, HBV and vaccination
against hepatitis B and other viral diseases for which there is a vaccine available. We must
also have a detailed description of their jobs, tasks and responsibilities. In addition the centre
must provide the worker training in freezing techniques for updating and improving
procedures.
• Use of open devices. In recent times there is much talk of closed or open system and the
possibility of contamination, so many countries have banned open systems and the trend is
to ban the high risk of sample contamination. In a closed or semi-closed device the nitrogen
of common container is never in contact with biological material frozen on the inside so
cross-contamination cannot produced. In the open system, the biological material is in
contact with the common nitrogen so contamination from the sample is very easy if the LN2
is contaminated or contamination of LN2 if the sample is contaminated. The latest study
done by Criado and his group [122] showed 45% of contamination in an open device
(Cryotop) Vs 0% of contamination in a semi-close device (Ultravit) equal and using a
contaminated laboratory LN2.
7.2. Cooling solution contamination
The cooling solution plays a significant role in avoiding contamination of biological samples.
It means that we will freeze the sample and we will deposit it for a long storage until thawed
and used. Normally the LN2 cooling solution is the most widely used in cryopreservation and
survival of pathogens at high temperatures (-196 ° C) has already been proven by many studies
[195-97,121,122] cases also involved in seeing cross-contamination of human papillomavirus
[108,123].
The need for better cooling rates to avoid formation of crystals in cryopreservation has resulted
in the discovery and use of new cooling solutions (slush, slurry, etc.). So there are more
components to consider when contamination is to be avoided. Using these new cooling
solutions gives a lower temperature than the LN2 temperature and much faster transmission.
The Slush nitrogen is obtained by a vacuum pump (Telstar TOP-3; Telstar S.A., Terrassa, Spain)
that solidifies part of the LN2 in a few minutes. On return to normal atmospheric pressure, the
nitrogen collapses, and the subcooled LN2 has solid particles in it commonly referred to as
‘‘slush’’ [124].The advantage of Slush nitrogen lies not only in the temperature difference with
respect to LN2 (-196°C Vs-210°C) but also in the reduction of the Leiden frost effect, which is
the formation of a layer of vapor around the sample when immersed in the cryogenic liquid
from room temperature decreasing the cooling rate [125,126]. It has not yet been demonstrated
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the survival or non survival of pathogens in this cooling solution of 15-20 ° C difference in
LN2, this is obtained by vacuum pressure, which can lead to rupture of the cell wall of
pathogens to balance internal and external pressure of these in the process of forming Slush.
The ‘Slurry’ nitrogen is a mix of LN2 with different particles for example copper powder. At
present investigations are being carried out as an alternative to LN2 to increase the cooling
rate because with this cooling solution the thermal conduction is increased. Likewise, experi‐
ments are ongoing with various solutions to increase the thermal conduction and the cooling
rate.
Table 1. Microbial contamination of embryos and semen during storage in liquid nitrogen (adapted from Bielanski et
al., 2003)
These cooling solutions "alternatives" are only used at the time of freezing the sample and once
frozen, it passes to the general container that is filled with LN2, although these solutions where
they freeze cool samples have to be sterile we have to ensure that the general LN2 container
does not have contact with the frozen sample in order to not contaminate the sample and the
LN2 if the sample is positive for any pathogen. Retrospective studies in which commercial
LN2 cryotanks were examined after 35 continuous years of service revealed various bacterial
and fungal contaminations in the LN2 detritus [117]. Many of the identified bacteria isolated
in these studies were ubiquitous environmental micro-organisms and were rare opportunistic
pathogens of low significance in producing disease in humans or animals (Table I). It should
be acknowledged that some of the isolates may have been derived from laboratory contami‐
nation during semen and embryo processing for cryopreservation rather than genuinely being
present within the sample. In agreement with Bielansky and Vajta the risk of contamination
by human pathogens seems to be rather low. Components of the standard LN2 production
system comprise a compressor, a cryogenerator and containers. From a practical point of view,
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the complete sterilization and maintenance of sterility in such a robust system might be a very
demanding task, if possible at all. Accordingly, some ubiquitous bacterial agents can be
expected in any commercially produced LN2. Nevertheless, it is an ‘in and out’ system and
only air-borne contaminants are supposed to enter it (LN2 compressor) via air used for LN2
production. As they are not air-borne, it is unlikely that viral agents of human concern such
as HIV, hepatitis and herpes viruses would enter the LN2 production system.
Microbiological contamination of embryos and semen during storage in LN2 [117]
One of the biggest discussions recently in the world of cryopreservation focuses on the
importance of the sterility of LN2. As shown in Table I and in total agreement with Bielansky
and Vajta and many other authors the commercial LN2 reaching our lab is not contaminated
enough to cause any infection to freeze biological material. The major problem is common
containers where the samples are deposited with a LN2 stored for months, years or even
decades in contact with many samples, which, many clinics do not empty and do not disinfect,
so it is in common containers where we can find the highest risk of contamination and cross
contamination.
As a possible solution to minimize the risk of freezing biological material some systems have
been proposed where we sterilize the LN2 and where we ensure that the sample is not in
contact with LN2 with the use of semi-close devices or devices that are the only ones that
guarantee a hermetic sealing of the device and avoid any risk of breakage of the solder thus
ensuring the aseptic samples. The fact that LN2 can be quickly and safely sterilized could
encourage the clinical application of human cell/tissue vitrification, both with open carriers
and with closed systems. The problem is that if this device is an open device and is passed to
the general container where all the other cryopreserved samples there is a huge risk of cross
contamination, so it has not helped.
• LN2 Filtration: One of the solutions that have been developed is the filtration of LN2. Air
Liquid has marketed CERALIN a liquid filtration system through LN2 ceramic filters. The
CERALIN ON LINE consists of two elements of liquid filtration connected in series and
inserted into a section of vacuum transfer line. The ceramic membrane is made from multiple
layers formed into a multi-channel element. It is housed in a vacuum insulated pipe, itself
installed close to the end-use point. The filter minimizes the pressure drop and avoids the
vaporization of the LN2. Thus it avoids nitrogen losses. Several sizes are available, depend‐
ing on the nitrogen flow. The efficiency of this equipment was investigated and proved in
laboratory. The filter is located downstream of the nitrogen vessel. During operation, LN2
flows through the filter and over the ceramic membrane. The result is high-purity LN2 with
a bacteria count of less than 1 CFU/L gas. Additionally, the large filtration area of the
membrane and low level of contamination of LN2 means it is likely to be several decades
before filter saturation.
• UV Sterilization: This method is based on emitting the minimum dose on UV radiation
necessary to kill micro-organisms that can survive at the boiling point of nitrogen (-196°C)
and which is irradiated in a temperature-controlled regimen, within a short time interval,
before the LN2 completely evaporates. The extremely radiation-resistant bacterium
Recent Advances in Cryopreservation102
Deinococcus radiodurans is inactivated (>-4log) by administe-ring 400.000 μWs/cm² per
each sterilization cycle. An adequate amount of UV radiation deactivates the growth of all
kinds of micro-organisms, from viruses like Hepatitis (which require an 8.000 UV dose) to
fungi like Aspergillus Niger (330.000 UV dose) [127]. At CRYO 2011 Dr. Parmegiani spoke
about a new dispositive of UV sterilization of the common containers with cells or tissues
inside but the scientific community thinks that is too dangerous biological samples exposed
to UV rays without any protection. Although his group is proposing special canisters "not
transparent" I think they have to do many more tests to rule out damage to the samples
because the common view is confirmed that UV light is harmful, even if used just overnight
decreased embryo developmental rates.
• LN2 Steam: As an alternative to hermetical storage in LN2, cryostorage contamination might
be avoided by storing the carrier containing the vitrified oocytes in LN2 vapour [128, 129].
However, Grout and Morris [130] maintain that storage in the vapour phase of LN2 still
carries a risk of sample contamination. Storage of semen in LN2 vapours was discarded
early in the development of sperm cryopreservation techniques and it was found that long-
term viability of sperm was reduced compared with LN2 storage [131,132]. However, recent
experiments with new materials have succeeded in developing the technique with accept‐
able results for both semen and embryos [133,134] and in our last experiment we demon‐
strated 0% of contamination in vapor nitrogen in an experimental contaminated laboratory
LN2 (non published). The drawback of the generalization of this form of storage is the need
for careful monitoring of temperature in different parts of the container, which makes the
marketing of these containers type [134] more difficult.
• Before entering discussions regarding the sterility in LN2 used for vitrification, we should
debate the use of communal containers, which is where cross-contamination can be found,
as there is a possibility that the “contaminated cells” could come into contact with each other,
and where a number of viruses and bacteria are found, which would never be found in the
commercial LN2.
7.3. Contamination in transport
To carry out a safe transportation of biological material we should clearly distinguish a number
of concepts [111].
1. Infectious substances: those that contain viable microorganisms (bacteria, virus, prions,
parasite, fungus) or bacterial toxins that are known or believed to cause disease in animals
or humans.
2. Diagnostic specimens: human or animal materials (body fluids, blood, tissue, tissue fluids,
etc.). Obtained for diagnostic or investigational [135].
Most often transported biological reproductive materials are cryopreserved semen donor and
follicular fluid when the laboratory is separated from the follicular puncture site. In both cases,
we consider the recommendations to follow are those of diagnostic specimens. There are
several documents related to the transport of biological material, such as the Universal Postal
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Union (UPU), the International Aviation Organization (ICAO) and International Air Transport
Association (IATA) [136-138].
At European level, all documents related to transport are based on the recommendations of
the Committee of Experts of the United Nations Dangerous Goods (UN) [139]. There is also a
european agreement on international transport of dangerous goods by road (ADR), approved
by RD 2115/9838 [140]. We will describe some aspects of the mentioned regulations on the
transport of diagnostic specimens. The basic system consists of packaging:
1. Primary container, watertight, leak proof, labeled and contains the sample. This container
should be wrapped in absorbent material. In terms of labeling, according to AEBT, if it is
a semen sample from a donor, must contain an alphanumeric code that identifies the donor
and the sample number of the donor. On the other hand, if the sample is for autologous
use may be noted also the surname of the patient [115].
2. Secondary container, sealed, leak-proof and protects the primary container. You can place
multiple primary containers wrapped in a secondary container. This should be sufficient
absorbent material used to protect all primary containers and avoid collisions between
them.
3. Outer shipping container: the secondary container is placed in a shipping package that
protects the secondary container and its contents from outside elements, such as physical
damage and water. The data forms, letters and other identifying information of the sample
should be placed taped outside the secondary container. The label for submitted materials
consists of:
a. Basic triple packaging.
b. Does not require signs from United Nations (UN).
c. No substances require pictogram or declaration from the sender.
d. Biological material for clinical use" must be indicated.
e. Tag address:
• Name, address of destination, as detailed as possible, and phone number.
• Name, address, telephone number and contact person at the semen bank.
f. The documents included with the storage conditions and special instructions for
shipping. One of the special considerations that we must have in mind when
transporting a sample of semen is not breaking the cold chain, so you must use a
container or LN2 as well as avoiding the possible use of dry ice.
g. Permission for import / export and declaration.
h. Label orientation.
i. Date and time of departure of Semen Bank [115].
The requirements to be met for local transport are as follows:
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1. Sealed and resistant containers.
2. Threaded tubes upright (rack, tray...).
3. Use of resistant boxes and perfect closure.
4. Secured box in the transport vehicle.
5. Appropriate Labeling.
6. Have the forms with necessary details.
7. Vehicle with kit (gloves, absorbent material, disinfectant, waste container, etc.).
You must ensure perfect coordination of transport between the sender, carrier and recipient
to ensure delivery. Thus, each party involved should carry out its part perfectly and appro‐
priately. So stand out from other actions that the sender must ensure the proper identification,
packaging, labeling and documentation according to established biosafety guidelines in the
"Recommendations of the Committee of Experts of the United Nations Transport of Dangerous
Goods" transporting must be kept in appropriate conditions (temperature, light...) the material
from which the sender receives it until it is delivered to your destination and have the
appropriate licenses to perform this type of transport, and finally, the recipient must confirm
with national authorities that the material can be legally imported.
According to AEBT [115], the possibility of returning a material that hasn’t been used should
be avoided, as a rule, the return of the semen that has been provided by the Bank, as it will
only accept the return of the displayed when you meet the following 3 conditions:
1. The sample wasn’t thawed.
2. You can demonstrate the integrity of the packaging (the seals are intact).
3. The temperature of the sample was maintained throughout the transport.
8. New techniques for in-vitro fertilization patients: Ultravitrification
Today the differences between Slow freezing and Vitrification are known worldwide. We all
know that slow freezing is characterized by a prolonged cooling curve and the use of low
concentrations of cryo-protectors generally ‘‘non-toxic’’ for the cells (1–2 M) with cell injury
due to ice formation [141] and that Vitrification is characterized by the rapid procedure and
the use of a high concentration of cryo-protectors (4-6M) to prevent cell damage that is toxic
to most mammalian cells [7,142-149].Thus, vitrification with a semi-close devices have a better
cooling rate without cross-contamination or novel cyopreservation techniques are needed that
allow rapid cooling to achieve vitrification in the absence of high concentration of CPA or if is
possible without CPA.
The requirements and relationships for conditions to achieve satisfactory vitrification in the
area of mammalian ART are well displayed in the equation of Yavin and Arav [151]
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Probability of vitrification=
Cooling and warming rates ×
Viscosity (CPA concentration)
Volume
Probability of vitrification by Yavin and Arav [151]
The main points to be gathered from this relationship are that the smaller volume of the
vitrification solution in which the cellular material is placed for the vitrification process, the
faster cooling and warming rate that can be achieved and the lower concentration of CPAs
needed reducing the detrimental effect of the inherent toxicity of CPAs and increasing the
overall success of the procedure.
What would happen if We could vitrify without CPA’s or with a low concentration of CPA’s?
What would happen if We could combine the advantages of Slow freezing and Vitrification
and vitrify with low concentrations of CPA’s with a secure and free contamination device?
That is Kinetic vitrification (Ultra-vitrification). Perfecting the techniques of Vitrification has
been achieved a morphological survival rate comparable to normal Vitrification protocol [123]
or a 59.1% of blastulation rate in mouse embryo [151] with Kinetic vitrification and concen‐
trations of CPA’s typical of Slow freezing.
 
What	is	the	necessary	cooling	rate?	
Slow	freezingVitrification	
What	would	happen	if	We	could	vitrify	without	CPA’s	or	with	a	low	concentration	of	CPA’s?	What	would	happen	if	We	could	combine	the	advantages	of	Slow	freezing	and	 Vitrification	 and	 vitrify	with	 low	 concentrations	 of	 CPA’s	with	 a	 secure	 and	free	 contamination	 device?	 That	 is	 Kinetic	 vitrification	 (Ultra‐vitrification).	Perfecting	 the	 techniques	 of	 Vitrification	 has	 been	 achieved	 a	 morphological	survival	 rate	 comparable	 to	 normal	 Vitrification	 protocol	 (123)	 or	 a	 59.1%	 of	blastulation	 rate	 in	 mouse	 embryo	 (151)	 with	 Kinetic	 vitrification	 and	concentrations	of	CPA’s	typical	of	Slow	freezing.		
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Figure 2. Necessary cooling rate to have a good probability of vitrification
Previous studies hav  tried to achieve high cooling rates for cell vitrificatio . However, none
of them utilized low CPA concentrations (1.5-2 M). In 1985, Rall and Fahy successfully vitrified
mouse embryos in 6.5 M cryoprotectant cocktail solution [7]. In that case the method consisted
in a 0.25 ml straw container plunged into LN2; the cooling rate was 2.500 °C/min. When this
container was plunged into Slush nitrogen, the cooling rate increased up to 4000 °C/min [152].
The use of OPS (instead of the 0.25 ml straw) in LN2 increases this cooling rate up to 5.300 °C/
min [152] and to 10.000–20.000 °C/min if plunged in Slush nitrogen [152,153]. Similar cooling
rates were ac ieved in the case of a Cryoloop quen hed in Slush nitrogen [154]. Th  use of
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electron microscope copper grids has also been investigated, but the cooling rates were in the
same order of magnitude that the afore mentioned works: 11.000–14.000 °C/min in the case of
plunging the grid in LN2 [155] and 24.000–30.000 °C/min if plunged in Slush nitrogen [126,
155]. From Boutron’s theory, none of these approaches reaches the critical cooling rate to
achieve vitrification with low concentration of CPA (1.5-2M). It´s impossible to use open
devices with Slush nitrogen as the cell is on the outside and there is a possibility of detaching
from the device.
Adjusting to Yavin and Arav formula the Ultra-vitrification technique arose achieving a
cooling rate above 250.000 °C/min and of 90.000 °C/min in thawing. This rate is one order of
magnitude higher than the highest cooling rate achieved in different strategies (electron
microscope copper grids in Slush nitrogen [126,155], whilst keeping all the advantages of a
straw-like form for the container and being in the range of the necessary cooling rate to achieve
vitrification. To have this increase in the cooling rate a few changes were made to the normal
vitrification process:
Slush Nitrogen
As a cooling agent this technique uses Slush nitrogen, much colder than LN2 (-196°c Vs-210°C)
and with the property of avoiding the Leiderfrost Effect. When something is submerged in
LN2, bubbles rise to the surface through the device, varying the thermal conductivity from the
outside into the inside of the device. This does not happen with Slush nitrogen. Slush nitrogen
is achieved with a vacuum pump in 5 to 10 minutes and it remains slush for a further 5 – 10
minutes before returning to liquid.
It was shown for oocytes and embryos that increasing the cooling rate would improve survival
rates by up to 37% [156]
 
Figure 3. Slush Nitrogen
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Quartz Micro-capillary
Another determining factor to achieve a high cooling rate is the device used. To increase the
thermal conductivity and minimize the volume, this technique has used a quartz microcapil‐
lary. This has a 0.2-0.3 diameter allowing to ultra-vitrify 0.1-0.2 μl with a 0.01mm wall, a lot
thinner than any other device (0.075 mm in OPS). Another important characteristic is the
material it is made from: Quartz. The thermal conductivity of quartz glass is a lot higher than
that of plastic of which other devices are made of. This converts it in one of the materials that
best conducts the temperature. [157]
		Xiaoming	He	et	al	(157)		In	a	thermal	performance	of	quartz	capillaries	 for	vitrification	done	by	Risco	and	his	 group	 (158)	 a	 commercially	 available	 version	 of	 the	 OPS	 (MTG	 Medical	Technological	Vertriebs,	GmbH)	was	used.	The	thermal	conductivity	of	these	PVC	straws	was	0.19	W	m_1	K_1.	The	inner	diameter	is	0.800	mm	and	the	thickness	of	its	wall	 is	 0.075	mm	 (Fig.	 1a).	 The	QC	used	 (The	Charles	 Supper	Company,	 Inc.)	have	 an	 inner	 diameter	 of	 0.180	 mm	 and	 a	 wall	 thickness	 of	 0.010	 mm.	 These	geometrical	 improvements	 (4.44	 times	 smaller	 in	 diameter	 and	 7.50	 times	thinner)	 translate	 not	 only	 into	 a	 faster	 heat	 transfer,	 but	 also	 into	 a	 20	 times	reduction	in	volume	of	the	contained	solution	(for	a	given	height).	This	is	beneficial	because	 the	 thermal	 conductivity	 of	 the	 quartz	 glass	 is	 1.3	 W	 m_1	 K_1,	 that	 is	almost	one	order	of	magnitude	higher	than	that	of	PVC.		
	(a)	 Thermal	 history	 for	 the	 OPS	 when	 filled	 with	 a	 1.5M	 propane‐1,2‐diol	 and	 0.3M	 sucrose	cryoprotectant	solution	quenched	in	LN2	and	then	thawed	in	a	water	bath	at	37ºC.		A	 clear	 heat	 release	 peak	 is	 present	 during	 cooling	 as	 well	 as	 melting	 during	rewarming.	 (b)	Thermal	history	 for	QC	when	 filled	with	a	1.5M	propane‐1,2‐diol	and	0.3M	sucrose	cryoprotectant	solution	quenched	in	LN2	and	then	thawed	in	a	water	 bath	 at	 37ºC.	 Crystallization	 of	 water	 is	 not	 obvious	 during	 cooling,	 but	melting	is	shown	during	rewarming.	(c)	Thermal	history	for	OPS	when	filled	with	a	
Figure 4. Xiaoming He et al [157]
In a thermal performance of quartz capillaries for it ificati n done by Risco and his group
[158] a commercially available version of the OPS (MTG Medical Technological Vertriebs,
GmbH) was used. The thermal conductivity of these PVC straws was 0.19 W m_1 K_1. The
inner diameter is 0.800 mm and the thickness of its wall is 0.075 mm (Fig. 1a). The QC used
(The Charles Supper Company, Inc.) have an inner diameter of 0.180 mm and a wall thickness
of 0.010 mm. These geometrical improvements (4.44 times smaller in diameter and 7.50 times
thinne ) translate n t only into a faster heat transfer, but also into a 20 times r duction in
volume of th  contained solution (for a given heigh ). Thi  is beneficial because the thermal
conductivity of the quartz glass is 1.3 W m_1 K_1, that is almost one order of magnitude higher
than that of PVC.
A clear heat release peak is present during cooling as well as melting during rewarming. (b)
Thermal history for QC when filled with a 1.5M propane-1,2-diol and 0.3M sucrose cryopro‐
tectant solution quenched in LN2 and then thawed in a water bath at 37°C. Crystallization of
water is not obvious during cooling, but melting is shown during rewarming. (c) Thermal
history for OPS when filled with a 1.5M propane-1,2-diol and 0.3 M sucrose cryoprotectant
solution quenched in Slush nitrogen and then thawed in a water bath at 37°C. In this case,
crystallization during cooling and melting during rewarming was not recorded. However,
visual inspection reveals the presence of ice. (d) Thermal history for QC when filled with a
1.5Mpropane-1,2-diol and 0.3 Msucrose cryoprotectant solution quenched in Slush nitrogen
and then thawed in a water bath at 37°C. The sample keeps its transparency over all the
cooling–rewarming cycle, an indication of the capability of this approach to vitrify the studied
solution. All these changes have allowed us to maintain a concentration of cryoprotectors
typical of slow freezing, 2 M PrOH+0.5 M sucrose, obtaining a morphological survival rate of
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92 % in human oocytes [124]. Dr. Ho-Joon Lee et al [151] tested this new technique on mouse
ooctyes and they saw that using Ultra-vitrification with low concentrations of cryoprotectors
improved the fertilization rate and above the blastulation rate. Only the use of Ultravit device
in this technique ensures the non contamination of the sample or cross-contamination in
communal containers.
% Slow freezing [159] Vitrification [159]
Ultravitrification
mourine oocytes
[151]
Ultravitrification
human oocytes [124]
Surv. rate 61 91.8 92.5 92
Fert. Rate 61.3 67.9 75 ?
Blast. rate 12 33.1 59.1 ?
Table 2. Comparison between slow Freezing, Vitrification and Ultravitrification [162,152,124]
This comparison demonstrates the use of low concentration of cryoprotectant in the Ultravi‐
trification protocol favours the morphological survival (92%) and increases the blastulation
rate (59.1%). Thus confirming the hypothesis that cryoprotectants are toxic to the biological
Figure 5. a) Thermal history for the OPS when filled with a 1.5M propane-1,2-diol and 0.3M sucrose cryoprotectant
solution quenched in LN2 and then thawed in a water bath at 37°C.
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sample and if we could find a vitrification protocol that would allow us to vitrify without
cryoprotectant, we would achieve a better embryo development and a greater chance of
pregnancy in the case of freezing eggs or embryos. A lot more studying is needed regarding
this new technique but a priori the results indicate that we can hopefully lower the concen‐
tration of the cryoprotectants decreasing the toxicity in cells.
9. Conclusion
Cryopreservation has always been a fundamental tool in assisted reproduction but increas‐
ingly assumed a more important role because it serves not only to optimize ART treatments
but thanks to the possibility of both cells and tissues cryopreserved successfully, we can offer
the possibility reproductive future of cancer patients.
Cryopreservation takes many utilities; the most traditional approach is optimization of IVF
treatments. In this sense it has been used in the cryopreservation of sperm for sperm banks or
uses it to treatment when there is a problem to get it on the day of egg retrieval. The sperm
freeze has been doing for decades due to the relative ease of the technique and the good results
are achieved, therefore it is more widespread use of sperm cryopreservation in cancer patients
or patients who are going to be vasectomized getting preserve their fertility for the future.
From the revolutionary emergence in the late 70's in vitro fertilization (IVF), the possibility of
storing surplus embryos from IVF programs was a need and offered an excellent alternative
Cryobiology. Other situations where cryopreservation is very useful are reported when an
embryo transfer is dangerous for the health of the patient for risk of ovarian hyperstimulation
(OHSS).
Another key point in recent years is gaining more importance is the freezing of oocytes. Because
of its large size and the amount of water that contains inside, the oocyte has always presented
difficulties for cryopreservation. The need for better cooling rates to avoid formation of crystals
in cryopreservation has resulted in the discovery and use of new cooling solutions (slush,
slurry, etc.). These new cooling solutions and the new vitrification media with little or no
cryoprotectant has become possible that cell cryopreservation excellent results after thawing.
Up to date, the studies that have evaluated the health of children born through the procedure
of egg thawing have reflected that there is no increase in the incidence of congenital abnor‐
malities. And it remits us to prestigious investigations such as that published by Noyes in 2009
[160] with nearly 900 babies born through freezing and thawing of oocytes, in which it reflected
that these children were completely normal. More recently Levi Setti in 2013 [161] published
another study in which it stated that, after studying 954 pregnancies, there is clear evidence
that the children born by this technique have the same probability of malformation and the
same complications during a pregnancy and delivery as children born by other assisted
reproduction techniques in which fresh eggs have been used.
Therefore, up-to-date no published investigation makes us believe that oocyte vitrification is
dangerous for the children that will be born as a benefit of the technique. Although 13 years
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later after the first slow-freeze birth, the number of reported babies born as a result of vitrified
oocytes is now approaching that of slow-frozen oocytes without any increasing risk in
congenital abnormalities [160]. Vitrification of oocytes does not appear to increase risks of
abnormal imprinting or disturbances in spindle formation or chromosome segregation [162].
It has the greatest potential for successful oocyte cryopreservation and with its increased
clinical application is showing a trend to greater consistency and better outcomes (similar to
outcomes between fresh or warmed oocytes). Vitrification of oocytes, when applied to properly
screened patients, will be a useful technology in reproductive medicine practice and will
constitute a major step forward in ART. Today these results and the constant research to
continue advancing to achieve even further improvements in the cryopreservation protocols
have allowed the creation of egg banks around the world like OVOBANK that provide patients
do not have to travel to find donors in cities where there isn´t a high variability of egg donors
with similars results to those treatments with fresh eggs.
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